Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Maravai Lifesciences Holdings (MRVI) Invested Capital (2020 - 2025)

Maravai Lifesciences Holdings has reported Invested Capital over the past 6 years, most recently at $403.8 million for Q4 2025.

  • Quarterly results put Invested Capital at $403.8 million for Q4 2025, down 53.75% from a year ago — trailing twelve months through Dec 2025 was $403.8 million (down 53.75% YoY), and the annual figure for FY2025 was $403.8 million, down 53.75%.
  • Invested Capital for Q4 2025 was $403.8 million at Maravai Lifesciences Holdings, down from $538.3 million in the prior quarter.
  • Over the last five years, Invested Capital for MRVI hit a ceiling of $1.4 billion in Q4 2022 and a floor of $403.8 million in Q4 2025.
  • Median Invested Capital over the past 5 years was $1.1 billion (2021), compared with a mean of $1.0 billion.
  • Biggest five-year swings in Invested Capital: soared 58.44% in 2022 and later plummeted 54.21% in 2025.
  • Maravai Lifesciences Holdings' Invested Capital stood at $1.1 billion in 2021, then skyrocketed by 33.15% to $1.4 billion in 2022, then fell by 8.28% to $1.3 billion in 2023, then tumbled by 33.55% to $873.1 million in 2024, then plummeted by 53.75% to $403.8 million in 2025.
  • The last three reported values for Invested Capital were $403.8 million (Q4 2025), $538.3 million (Q3 2025), and $761.9 million (Q2 2025) per Business Quant data.